Second Messenger Nucleotides of Enterococcus faecalis
粪肠球菌第二信使核苷酸
基本信息
- 批准号:10672673
- 负责人:
- 金额:$ 43.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-17 至 2023-03-16
- 项目状态:已结题
- 来源:
- 关键词:AgonistAntibiotic TherapyAntibioticsAreaAttenuatedBacteriaBindingBiological ProcessCell MaintenanceCell physiologyCellsCellular Metabolic ProcessCharacteristicsClinicalComplexCuesCyclic NucleotidesDataDiseaseDisinfectantsEnterococcusEnterococcus faecalisEnterococcus faeciumEnvironmentExposure toFunctional disorderGastrointestinal tract structureGoalsGrowthHomeostasisHospitalsHumanImmune responseImmune systemImpairmentInfectionInnate Immune ResponseInterferon Type IInvestigationKnowledgeLeadLightLinkMechanicsMediatingMetabolismMicrobial BiofilmsMulti-Drug ResistanceNosocomial InfectionsNucleotidesOsmoregulationPathogenesisPathogenicityPatientsPhysiologicalPlayPrimary InfectionProcessProductionProteinsPublic HealthRegulationResearchResearch DesignRoleSecond Messenger SystemsSignal TransductionSolidStimulusStressSurfaceTimeTissuesVirulenceWorkantibiotic toleranceantimicrobialbacterial fitnessbasecatheter associated UTIcell envelopecellular targetingfitnessimplantable deviceinnovationinsightinterestmouse modelmulti-drug resistant pathogennovelopportunistic pathogenpathogenrational designresident commensalsresistant strainresponsestress resiliencetrait
项目摘要
ABSTRACT
Enterococci are the 3rd most common cause of hospital-acquired infections and a major public health threat
due to the continuous rise of multidrug-resistant (MDR) isolates. Because the pathogenic potential of
enterococci is closely linked to their ubiquitous stress resilience, work in our lab aims to identify and dissect the
mechanisms that allow Enterococcus faecalis, the most prevalent enterococcal species of human infections, to
survive in the hostile host environment. Second messenger nucleotides such as (p)ppGpp (the effector
molecule of the stringent response) and c-di-AMP are produced by bacteria in response to internal or external
stimuli, playing major roles in the regulation of processes associated with cell homeostasis and virulence. In
addition, cyclic nucleotides such as c-di-AMP act as agonists of the innate immune response of mammalians by
stimulating a potent STING-dependent type I interferon response. Of interest, previous investigations have
shown that the c-di-AMP and (p)ppGpp networks are interconnected in other bacteria, but a clear
understanding of the mechanics and physiological significance of this interaction are still lacking. In previous
studies, we discovered that E. faecalis depends on small amounts of (p)ppGpp to maintain a balanced
metabolism and to respond to external cues in an accurate and timely manner. We also found that lack of
(p)ppGpp greatly increases antibiotic sensitivity and attenuates the virulence of E. faecalis. More recently, we
showed that c-di-AMP is also critical to E. faecalis pathophysiology and that either accumulation or lack of c-
di-AMP can drastically impair the virulence potential of E. faecalis. The goals of this application are: (i) to
probe the multifaceted roles played by c-di-AMP during infection using a catheter-associated urinary tract
infection (CAUTI) mouse model that recapitulates many of the clinical characteristics of the disease in humans,
(ii) to identify and characterize the c-di-AMP binding/effector proteins in E. faecalis, and (iii) to investigate
how integration of the c-di-AMP and (p)ppGpp networks controls specific processes that promote bacterial
fitness and then determine how this association contributes to E. faecalis pathophysiology. This conceptually
innovative application builds on our extensive preliminary data and the complementary expertise and solid
track record of our research team in each specific area of this application. Significance of the proposed
studies lies in unravelling the multifaceted role of c-di-AMP in host-pathogen interactions, uncovering the
scope of c-di-AMP regulation in a major MDR pathogen, and shedding new light onto the intricate relationship
between c-di-AMP and (p)ppGpp signaling networks. Given the central role of second messenger nucleotides in
bacterial pathogenesis, a better understanding of how they modulate cell physiology based on the identification
and characterization of their mechanisms of action and effectors can facilitate the rational design of new
antimicrobial therapies.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jose A Lemos其他文献
Jose A Lemos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jose A Lemos', 18)}}的其他基金
Mechanisms of Metal Ion Homeostasis of Oral Streptococci
口腔链球菌金属离子稳态机制
- 批准号:
10680956 - 财政年份:2023
- 资助金额:
$ 43.91万 - 项目类别:
Second Messenger Nucleotides of Enterococcus faecalis
粪肠球菌第二信使核苷酸
- 批准号:
10676471 - 财政年份:2023
- 资助金额:
$ 43.91万 - 项目类别:
Role of the Spx Regulator in Streptococcus mutans
Spx 调节剂在变形链球菌中的作用
- 批准号:
8211850 - 财政年份:2010
- 资助金额:
$ 43.91万 - 项目类别:
Role of the Spx Regulator in Streptococcus mutans
Spx 调节剂在变形链球菌中的作用
- 批准号:
8402631 - 财政年份:2010
- 资助金额:
$ 43.91万 - 项目类别:
相似海外基金
SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
- 批准号:
2213034 - 财政年份:2023
- 资助金额:
$ 43.91万 - 项目类别:
Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
- 批准号:
10645528 - 财政年份:2023
- 资助金额:
$ 43.91万 - 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
- 批准号:
10736285 - 财政年份:2023
- 资助金额:
$ 43.91万 - 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
- 批准号:
10603486 - 财政年份:2023
- 资助金额:
$ 43.91万 - 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 43.91万 - 项目类别:
Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
- 批准号:
422034 - 财政年份:2020
- 资助金额:
$ 43.91万 - 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
- 批准号:
nhmrc : 1197866 - 财政年份:2020
- 资助金额:
$ 43.91万 - 项目类别:
Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
- 批准号:
2241853 - 财政年份:2019
- 资助金额:
$ 43.91万 - 项目类别:
Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
- 批准号:
18K07106 - 财政年份:2018
- 资助金额:
$ 43.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
- 批准号:
9788269 - 财政年份:2018
- 资助金额:
$ 43.91万 - 项目类别: